Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.
Valeria CentoThi Huyen Tram NguyenDomenico Di CarloElisa BiliottiLaura GianserraIlaria LenciDaniele Di PaoloVincenza CalvarusoElisabetta TetiMaddalena CerroneDante RomagnoliMichela MelisElena DanieliBarbara MenzaghiEnnio PolilliMassimo SicilianoLaura Ambra NicoliniAntonio Di BiagioCarlo Federico MagniMatteo BolisFrancesco Paolo AntonucciVelia Chiara Di MaioRoberta AlfieriLoredana SarmatiPaolo CasalinoSergio BernardiniValeria MicheliGiuliano RizzardiniGiustino ParrutiTiziana QuirinoMassimo PuotiSergio BabudieriAntonella D'Arminio MonforteMassimo AndreoniAntonio CraxìMario AngelicoCaterina PasquazziGloria TalianiJeremie GuedjCarlo-Federico PernoFrancesca Ceccherini-SilbersteinPublished in: PloS one (2017)
Our data support a process of HCV-clearance by all-DAA regimens potentiated by NS5A-inhibitor, and less relying upon hepatocyte death than IFN-containing regimens. This may underline a process of "cell-cure" by DAAs, leading to a fast improvement of liver homeostasis.